(MedPage Today) — The FDA approved garetosmab (Pasatru) to reduce the formation of new heterotopic ossification lesions and disease flares in adults with fibrodysplasia ossificans progressiva (FOP), the agency announced on Wednesday.
A monoclonal…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
